BTIG raised the firm’s price target on Penumbra (PEN) to $270 from $232 and keeps a Buy rating on the shares. The MedTech tape has been up 3.2% since earnings season kicked off on October 15, the analyst tells investors in a research note. Following the U.S. election, BTIG believes devices, an area that generally gets bipartisan support, should be in a stronger relative position within the healthcare landscape under various scenarios.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra price target raised to $250 from $235 at Piper Sandler
- Penumbra’s CAVT technology shows benefits in pulmonary embolism
- Penumbra price target raised to $232 from $222 at RBC Capital
- Penumbra price target raised to $235 from $225 at Piper Sandler
- Penumbra price target raised to $248 from $244 at Baird